导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.57% | 1301/4773 |
| 近一周 | -2.27% | 4209/5467 |
| 近一月 | -4.50% | 1763/5421 |
| 近一季 | -3.87% | 1519/5238 |
| 近半年 | -2.38% | 2298/4931 |
| 近一年 | 10.89% | 975/4400 |
| 近两年 | 89.26% | 723/2954 |
| 近三年 | 64.67% | 406/2253 |
| 成立以来 | 136.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.14% 1043/4961 |
11.04% 2374/5312 |
- - |
- - |
| 2025 | 43.53% 664/4813 |
5.11% 828/3635 |
7.62% 373/4076 |
21.16% 1839/4524 |
4.72% 498/4813 |
| 2024 | 9.62% 1457/3463 |
-5.42% 1894/2808 |
-1.38% 1053/3014 |
14.41% 1979/3129 |
2.71% 904/3463 |
| 2023 | -5.31% 725/2656 |
1.59% 1543/2280 |
-1.31% 470/2385 |
-5.20% 1290/2515 |
-0.37% 206/2655 |
| 2022 | -32.88% 1690/2207 |
-16.20% 1113/1919 |
3.47% 1147/2016 |
-20.74% 1873/2113 |
-2.33% 1796/2208 |
| 2021 | 9.70% 451/1822 |
-5.73% 951/1255 |
15.81% 221/1330 |
-4.89% 747/1466 |
5.64% 278/1822 |
| 2020 | 32.64% 480/1250 |
-1.21% 209/1028 |
24.39% 171/1067 |
1.05% 1032/1164 |
6.82% 743/1184 |
| 2019 | 61.06% 49/1092 |
34.21% 118/754 |
-4.87% 443/804 |
15.14% 17/850 |
9.56% 221/918 |
| 2018 | -26.26% 378/834 |
- - |
- - |
- - |
-13.79% 555/691 |
| 2017 | 4.73% 384/714 |
- - |
- - |
- - |
- - |
| 2016 | -19.60% 435/605 |
- - |
- - |
- - |
- - |
| 2015 | 26.36% 87/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发百发100指数A VS. 长安沪深300非周期A(740101) |